The distinct effects of vilazodone on the 5-HTT and 5-HT1A receptors may enhance serotonergic transmission to achieve clinical efficacy in depression while limiting the adverse events of SSRI-induced sexual dysfunction. Here, HTR1A is linked to depressive symptom measurement.